Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845360 | 0.87 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL6305556 | 0.81 | CRHR1 (0.45) | CRHR1 | |
| SCHEMBL5843511 | 0.76 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL6310594 | 0.76 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL5845650 | 0.73 | CRHR1 (0.39) | CRHR1 | |
| SCHEMBL5844199 | 0.73 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL5611393 | 0.69 | CRHR1 (0.52) | CRHR1 | |
| SCHEMBL5843198 | 0.69 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL5611294 | 0.67 | CRHR1 (0.44) | CRHR1 | |
| SCHEMBL6398386 | 0.67 | CRHR1 (0.44) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0925298-B1 | SUBSTITUTED 6,6-HETERO-BICYCLIC DERIVATIVES | PFIZER (US) | 2004-04-14 | — | — | EP | claimed |
| US-20030114671-A1 | Substituted6,6-hetero-bicyclicderivatives | CHEN YUHPYNG L (US) | 2003-06-19 | — | — | US | claimed |
| US-6875769-B2 | Substituted6,6-hetero-bicyclicderivatives | PFIZER INC. (US) | 2005-04-05 | — | — | US | disclosed |
| EP-0925298-B1 | SUBSTITUTED 6,6-HETERO-BICYCLIC DERIVATIVES | PFIZER (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030114671-A1 | Substituted6,6-hetero-bicyclicderivatives | CHEN YUHPYNG L (US) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114671-A1 | Substituted6,6-hetero-bicyclicderivatives | CYP2D6, CYP2B6, CYP2A6 | CRHR1 2119/4885MEN1 1562/4885KMT2A 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.